The role of oral vancomycin in inducing remission for biologic-experienced ulcerative colitis with concomitant primary sclerosing cholangitis and liver transplantation
Authors:
- 1 November 2020
- journal article
- case report
- Published by Springer Nature in Clinical Journal of Gastroenterology
- Vol. 14 (1) , 159-164
Abstract
While a minority of patients with ulcerative colitis has primary sclerosing cholangitis (PSC), a significant proportion of patients with PSC have ulcerative colitis. The activity of PSC is usually not commensurate with the degree of concomitant colonic inflammation. Moreover, up to one-third of patients with a history of ulcerative colitis may paradoxically experience worsening of their colonic inflammation despite receiving immunosuppression after liver transplantation for PSC. There is a dearth of data pertaining to the management of ulcerative colitis in this post-transplantation patient population. We hereby delineate the case of a patient with severe refractory ulcerative colitis in the aftermath of liver transplantation due to PSC who eventually responded to oral vancomycin after failure of biologic therapy. Since current data implicate that patients with ulcerative colitis and PSC often present with distinct alterations of their colonic microbiome, oral vancomycin may be conjectured to demonstrate a therapeutic role. In this article, the review of literature suggests that oral vancomycin might indeed be an effective substitute in patients in whom the uptake of biologic agents may be challenging owing to their already immunosuppressed status.Keywords
This publication has 31 references indexed in Scilit:
- Pathogenesis of Primary Sclerosing Cholangitis and Advances in Diagnosis and ManagementGastroenterology, 2013
- Dense genotyping of immune-related disease regions identifies nine new risk loci for primary sclerosing cholangitisNature Genetics, 2013
- Immunomodulatory Effect of Vancomycin on Treg in Pediatric Inflammatory Bowel Disease and Primary Sclerosing CholangitisJournal of Clinical Immunology, 2012
- Reduced Acquisition and Overgrowth of Vancomycin-Resistant Enterococci and Candida Species in Patients Treated With Fidaxomicin Versus Vancomycin for Clostridium difficile InfectionClinical Infectious Diseases, 2012
- Diagnosis and Management of Primary Sclerosing CholangitisHepatology, 2010
- OPT-80 Eliminates Clostridium difficile and Is Sparing of Bacteroides Species during Treatment of C. difficile InfectionAntimicrobial Agents and Chemotherapy, 2009
- Long‐term Treatment of Primary Sclerosing Cholangitis in Children With Oral Vancomycin: An Immunomodulating AntibioticJournal of Pediatric Gastroenterology and Nutrition, 2008
- Different bacterial gene expression patterns and attenuated host immune responses are associated with the evolution of low-level vancomycin resistance during persistent methicillin-resistant Staphylococcus aureus bacteraemiaBMC Microbiology, 2008
- PSC-IBD: a unique form of inflammatory bowel disease associated with primary sclerosing cholangitisGut, 2004
- Double blind controlled trial of oral vancomycin as adjunctive treatment in acute exacerbations of idiopathic colitis.Gut, 1985